Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.

This publication has 47 references indexed in Scilit:

• Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizers
  Biochemical and Biophysical Research Communications, 1984
• Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation
  FEBS Letters, 1984
• Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine‐type polymorphism of drug oxidation
  European Journal of Clinical Investigation, 1984
• Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs
  Life Sciences, 1984
• Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes
  Biochemistry, 1983
• Identification of Tissue-Specific Nuclear Antigens Transferred to Nitrocellulose from Polyacrylamide Gels
  Science, 1981
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
  Proceedings of the National Academy of Sciences, 1979
• Spectral analysis of a solubilized hepatic cytochrome P-450 preparation for determination of contamination by cytochrome b5 and unreactive cytochrome P-450
  Chemico-Biological Interactions, 1974
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
  Nature, 1970
• On the Evaluation of the Constants V _m and K _M in Enzyme Reactions
  Science, 1952